Point32Health medical drug program updates
Point32Health updated prior authorization requirements and coverage criteria for 7 medical benefit drugs across multiple plans, effective August 1 and October 1, 2026. Key changes include: Vyjuvek now covers all ages (not age-restricted), Zolgensma requires documentation of no prior gene therapy, Epioxa no longer requires prior auth for keratoconus, Imaavy has updated PA criteria, Vykoura added to step therapy, Starjemza becomes preferred ustekinumab product, and Adstiladrin PA management moved to OncoHealth.